Berberine suppresses androgen receptor signaling in prostate cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The androgen receptor (AR) plays a crucial role in prostate cancer development and progression.
• Androgen deprivation therapy is a primary treatment for advanced prostate cancer, but resistance often develops, leading to castration-resistant prostate cancer (CRPC).
• Continued AR activation, even without ligands, is implicated in CRPC development, highlighting the need for novel AR-targeting agents.

Purpose of the Study:

• To investigate the effects of berberine on androgen receptor (AR) signaling pathways in prostate cancer.
• To determine if berberine can suppress AR activity and impact prostate cancer cell growth.
• To evaluate berberine's potential as a therapeutic agent for prostate cancer, particularly CRPC.

Main Methods:

• Assessing the impact of berberine on AR transcriptional activity and AR mRNA expression.
• Investigating berberine's effect on full-length AR protein and AR splice variants degradation.
• Evaluating berberine's efficacy in inhibiting LNCaP xenograft tumor growth in nude mice and analyzing AR expression in tumors and normal prostate tissue.

Main Results:

• Berberine significantly decreased AR transcriptional activity.
• Berberine induced the degradation of AR protein, including AR splice variants, without affecting AR mRNA levels.
• Berberine inhibited the growth of LNCaP xenografts and reduced AR expression in tumors, with no observed effects on normal prostate morphology or AR expression.

Conclusions:

• Berberine effectively suppresses AR signaling in prostate cancer by promoting AR protein degradation.
• Berberine demonstrates particular efficacy against AR splice variants, which are associated with CRPC.
• Berberine shows potential as a novel therapeutic or preventive agent for prostate cancer, warranting further investigation of its derivatives.